According to the UnivDatos, The molecular diagnostics market was valued at approximately USD 16.15 billion in 2024 and is expected to grow at a substantial CAGR of around 7.3% during the forecast period (2025-2033), owing to the rising demand for early and accurate disease detection.The global Molecular Diagnostics market has several major players, including Abbott, BD, Thermo Fisher Scientific Inc., Qiagen N.V., and Danaher. More information about these companies has been provided below:

1.      Abbott

The company Abbott from Illinois maintains a dominant position within the molecular diagnostics field, where it serves infectious diseases alongside oncology and genetic testing. The automated and rapid molecular testing solutions are provided through Alinity m and ID NOW platforms. The quick COVID-19 tests from Abbott gained the company massive fame, and the business now expands its testing range for medical facilities across hospitals and labs, and clinics. Through its business model, the company strives to speed up the process of molecular testing while expanding its accessibility to various healthcare facilities.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/molecular-diagnostics-market?popup=report-enquiry

2.      BD

The medical products company BD runs its molecular-diagnostic operations through the BD Life Sciences segment, which is based in New Jersey. The BD MAX System represents a program offered by the company that runs automated PCR testing for infectious disease detection, coupled with hospital-acquired infection discovery and antimicrobial resistance evaluation. BD operates in the field of laboratory efficiency and diagnostic speed improvement. The company dedicates its recent growth to expanding its disease portfolio for critical healthcare requirements, including prevention against drug-resistant pathogens and future pandemic emergencies.

3.      Thermo Fisher Scientific Inc.

Thermo Fisher Scientific maintains its Massachusetts location to provide molecular diagnostic tools, which include products for PCR and next-generation sequencing applications. Applied Biosystems produces essential diagnostic products that support infection detection, together with oncology tests and genetic analysis of biological materials. As part of its business activities, Thermo Fisher works with pharmaceutical entities toward developing diagnostic systems that align with prescription drugs. The organization delivers complete molecular solutions to support both clinical research laboratories.

4.      Qiagen N.V.

Qiagen operates its main business units from both the Netherlands and Maryland within the United States. QIAstat-Dx and NeuMoDx are among the popular molecular diagnostic platforms that the company provides for patients who need testing in infectious diseases and oncology, along with genetics. The complete process of sample preparation through result interpretation is provided by Qiagen as a single workflow solution. The organization develops active partnerships with pharmaceutical firms for the creation of personalized treatments and companion diagnoses.

Click here to view the Report Description & TOC https://univdatos.com/reports/molecular-diagnostics-market

5.      Danaher Corporation